Drug Trial Radar · NCT07647614
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Jan 1, 2030
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- Energenesis Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is: Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment? Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease. Participants will: * Take the study drugs twice a day for 72 weeks in the treatment group * Take routine use of standard-of-care antiparkinsonian medications throughout the study * Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests
Conditions
- Parkinson's Disease (PD)
Interventions
60 milligrams of ENERGI-F705 TabletsDrug
Tablets will be taken orally twice a day
Placebo tabletsDrug
Tablets will be taken orally twice a day.
120 milligrams of ENERGI-F705 TabletsDrug
Tablets will be taken orally twice a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants experiencing adverse events (AE) and serious adverse events (SAE)Time frame: From Day 1 to Week 76
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Neurology, Shuang Ho Hospital
New Taipei City, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.